144 related articles for article (PubMed ID: 32576238)
1. Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors.
Guo H; Ding Q; Gong Y; Gilcrease MZ; Zhao M; Zhao J; Sui D; Wu Y; Chen H; Liu H; Zhang J; Resetkova E; Moulder SL; Wang WL; Huo L
Breast Cancer Res; 2020 Jun; 22(1):69. PubMed ID: 32576238
[TBL] [Abstract][Full Text] [Related]
2. Comparison of SP142 and 22C3 PD-L1 assays in a population-based cohort of triple-negative breast cancer patients in the context of their clinically established scoring algorithms.
Sigurjonsdottir G; De Marchi T; Ehinger A; Hartman J; Bosch A; Staaf J; Killander F; Niméus E
Breast Cancer Res; 2023 Oct; 25(1):123. PubMed ID: 37817263
[TBL] [Abstract][Full Text] [Related]
3. PD-L1 Expression in Metaplastic Breast Carcinoma Using the PD-L1 SP142 Assay and Concordance Among PD-L1 Immunohistochemical Assays.
Grabenstetter A; Jungbluth AA; Frosina D; Hoda R; Dos Anjos CH; Patil S; Sevilimedu V; Weigelt B; Reis-Filho JS; Zhang H; Traina T; Robson ME; Brogi E; Wen HY
Am J Surg Pathol; 2021 Sep; 45(9):1274-1281. PubMed ID: 34115674
[TBL] [Abstract][Full Text] [Related]
4. Discordance in PD-L1 expression using 22C3 and SP142 assays between primary and metastatic triple-negative breast cancer.
Miyakoshi J; Yazaki S; Shimoi T; Onishi M; Saito A; Kita S; Yamamoto K; Kojima Y; Sumiyoshi-Okuma H; Nishikawa T; Sudo K; Noguchi E; Murata T; Shiino S; Takayama S; Suto A; Fujiwara Y; Yoshida M; Yonemori K
Virchows Arch; 2023 Dec; 483(6):855-863. PubMed ID: 37668667
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer.
Rugo HS; Loi S; Adams S; Schmid P; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Winer EP; Kockx MM; Peeters D; Chui SY; Lin JC; Nguyen-Duc A; Viale G; Molinero L; Emens LA
J Natl Cancer Inst; 2021 Nov; 113(12):1733-1743. PubMed ID: 34097070
[TBL] [Abstract][Full Text] [Related]
6. Expression of the immune checkpoint VISTA in breast cancer.
Zong L; Mo S; Yu S; Zhou Y; Zhang M; Chen J; Xiang Y
Cancer Immunol Immunother; 2020 Aug; 69(8):1437-1446. PubMed ID: 32266446
[TBL] [Abstract][Full Text] [Related]
7. Assessment of outcomes and novel immune biomarkers in metaplastic breast cancer: a single institution retrospective study.
Morgan E; Suresh A; Ganju A; Stover DG; Wesolowski R; Sardesai S; Noonan A; Reinbolt R; VanDeusen J; Williams N; Cherian MA; Li Z; Young G; Palettas M; Stephens J; Liu J; Luff A; Ramaswamy B; Lustberg M
World J Surg Oncol; 2020 Jan; 18(1):11. PubMed ID: 31937323
[TBL] [Abstract][Full Text] [Related]
8. Variable Landscape of PD-L1 Expression in Breast Carcinoma as Detected by the DAKO 22C3 Immunohistochemistry Assay.
Danziger N; Sokol ES; Graf RP; Hiemenz MC; Maule J; Parimi V; Palmieri C; Pusztai L; Ross JS; Huang RSP
Oncologist; 2023 Apr; 28(4):319-326. PubMed ID: 36866462
[TBL] [Abstract][Full Text] [Related]
9. Comparison of PD-L1 (22C3) Expression in Paired Primary and Metastatic Breast Carcinoma.
Huang X; Anderson SA; Siegal GP; Wei S; Liu S; Yang J; Roisin P; Pickens JT; Huo L; Sahin AA; Granada CP; Chen S
Clin Breast Cancer; 2024 Feb; ():. PubMed ID: 38492995
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes.
Ali HR; Glont SE; Blows FM; Provenzano E; Dawson SJ; Liu B; Hiller L; Dunn J; Poole CJ; Bowden S; Earl HM; Pharoah PD; Caldas C
Ann Oncol; 2015 Jul; 26(7):1488-93. PubMed ID: 25897014
[TBL] [Abstract][Full Text] [Related]
11. PD-1 and PD-L1 Expression in Male Breast Cancer in Comparison with Female Breast Cancer.
Manson QF; Ter Hoeve ND; Buerger H; Moelans CB; van Diest PJ
Target Oncol; 2018 Dec; 13(6):769-777. PubMed ID: 30519815
[TBL] [Abstract][Full Text] [Related]
12. PD-1(+) immune cell infiltration inversely correlates with survival of operable breast cancer patients.
Sun S; Fei X; Mao Y; Wang X; Garfield DH; Huang O; Wang J; Yuan F; Sun L; Yu Q; Jin X; Wang J; Shen K
Cancer Immunol Immunother; 2014 Apr; 63(4):395-406. PubMed ID: 24514954
[TBL] [Abstract][Full Text] [Related]
13. Expression of programmed death ligand-1 and programmed death-1 in samples of invasive ductal carcinoma of the breast and its correlation with prognosis.
Zhou T; Xu D; Tang B; Ren Y; Han Y; Liang G; Wang J; Wang L
Anticancer Drugs; 2018 Oct; 29(9):904-910. PubMed ID: 30085937
[TBL] [Abstract][Full Text] [Related]
14. Prevalence Study of PD-L1 SP142 Assay in Metastatic Triple-negative Breast Cancer.
Li Y; Vennapusa B; Chang CW; Tran D; Nakamura R; Sumiyoshi T; Hegde P; Molinero L
Appl Immunohistochem Mol Morphol; 2021 Apr; 29(4):258-264. PubMed ID: 33030848
[TBL] [Abstract][Full Text] [Related]
15. Scoring PD-L1 Expression in Urothelial Carcinoma: An International Multi-Institutional Study on Comparison of Manual and Artificial Intelligence Measurement Model (AIM-PD-L1) Pathology Assessments.
Rüschoff J; Kumar G; Badve S; Jasani B; Krause E; Rioux-Leclercq N; Rojo F; Martini M; Cheng L; Tretiakova M; Mitchell C; Anders RA; Robert ME; Fahy D; Pyle M; Le Q; Yu L; Glass B; Baxi V; Babadjanova Z; Pratt J; Brutus S; Karasarides M; Hartmann A
Virchows Arch; 2024 Apr; 484(4):597-608. PubMed ID: 38570364
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of programmed cell death ligand-1 expression in breast cancer: A meta-analysis.
Zhang Y; Tian J; Qu C; Tang Z; Wang Y; Li K; Yang Y; Liu S
Medicine (Baltimore); 2020 Dec; 99(49):e23359. PubMed ID: 33285715
[TBL] [Abstract][Full Text] [Related]
17. Concordance of PD-L1 expression in triple-negative breast cancers in Chinese patients: A retrospective and pathologist-based study.
Chen C; Ma X; Li Y; Ma J; Yang W; Shui R
Pathol Res Pract; 2022 Oct; 238():154137. PubMed ID: 36152566
[TBL] [Abstract][Full Text] [Related]
18. The Role of Stromal Tumour Infiltrating Lymphocytes (sTIL) Intensity and Programmed Death Ligand 1 () Expression in Breast Cancer Response to Neoadjuvant Therapy in Cipto Mangunkusumo Hospital (CMH), Indonesia.
Rustamadji P; Felicia D; Wuyung PE; Hellyanti T
Asian Pac J Cancer Prev; 2023 Oct; 24(10):3459-3465. PubMed ID: 37898851
[TBL] [Abstract][Full Text] [Related]
19. Programmed Death-Ligand 1 Expression in Breast Cancer Patients: Clinicopathological Associations from a Single-Institution Study.
Ayoub NM; Fares M; Marji R; Al Bashir SM; Yaghan RJ
Breast Cancer (Dove Med Press); 2021; 13():603-615. PubMed ID: 34803400
[TBL] [Abstract][Full Text] [Related]
20. PD-L1 expression in angiomatoid fibrous histiocytoma.
Byers J; Yin H; Rytting H; Logan S; He M; Yu Z; Wang D; Warren M; Mangray S; Dehner LP; Zhou S
Sci Rep; 2021 Jan; 11(1):2183. PubMed ID: 33500467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
